AGP Picks
View all

Asia Healthcare Industry Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.

Press releases published on July 10, 2026

How One Man's Personal Data Helped Him Control Type 2 Diabetes and Lose Weight — And How Readers Can Do the Same
Neuroradiologist Dr. Mistry Launches Mind of Mistry, a Podcast Exploring Longevity, Neuroscience, and Human Potential
Anti-Counterfeit Packaging Market Insights Report Analyzing Demand Trends And Competitive Positioning
Bispecific Monoclonal Antibodies Market To Reach $53 Billion By 2030 Driven By Expanding Industry Demand
BAT (Botulism Antitoxin Heptavalent) Market Research By The Business Research Company, Highlights Future Industry Trends
AAIC 2026 逾 140 份学术报告均采用 Alamar Biosciences NULISA 数据,彰显阿尔茨海默病血液生物标志物分析领域的进展
Alamar Biosciences 的 NULISA 數據將於 AAIC 2026 上超過 140 場科學簡報會中亮相,突顯基於血液的阿茲海默症生物標記剖析之最新進展
Canadian Red Cross opens appeal to support people impacted by flooding in Manitoba
La Croix-Rouge canadienne met sur pied un fonds de secours pour aider les personnes touchées par les inondations au Manitoba
China External Fixation and Orthopedic Instrument Manufacturers for Indonesia’s Hospital Procurement Market
Top 10 China Orthopedic Trauma Implant Manufacturers for the Middle East Market
GuideAI Health Announces Marketing and Communications Programs
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
SoliVana Wellness Lab Celebrates 3 years in Redwood City as the Bay Area's First Dedicated Nervous System Recovery Center
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Asia Healthcare Industry Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.